Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis

被引:56
作者
Yutani, K
Shiba, E
Kusuoka, H
Tatsumi, M
Uehara, T
Taguchi, T
Takai, SI
Nishimura, T
机构
[1] Osaka Univ, Sch Med, Div Tracer Kinet, Biomed Res Ctr, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Sch Med, Div Surg Oncol, Ctr Biomed Res, Suita, Osaka 5650871, Japan
[3] Kaizuka City Hosp, Dept Radiol, Osaka 5970015, Japan
关键词
breasts; neoplasms; F-18]2-deoxy-2-fluora-D-glucose; positron emission computed tomography; Tc-99m-methoxyisobutylisonitrile; single photon emission computed tomography;
D O I
10.1097/00004728-200003000-00017
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this work was to compare [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET and Tc-99m-methoxyisobutylisonitrile (MIBI) SPECT in the detection of breast cancer and axillary lymph node metastasis in the same patients. Method: FDG-PET and MIBI-SPECT were performed within 3 days for 40 women (age range 25-86 years old) with suspected breast cancer, in whom biopsies and/or mastectomies were performed. Both images were visually assessed, and the count ratio between tumor and normal tissue (T/N ratio) was calculated. Results: Thirty-eight patients had breast cancer, and the remaining two had benign breast lesions. The sensitivities of FDG-PET and MIBI-SPECT were 78.9 and 76.3% for breast cancer and 50.0 and 37.5% for axillary lymph node metastasis, respectively. The T/N ratio of breast cancer was significantly higher in FDG-PET (6.01 +/- 3.08 mean +/- SD) than that in MIBI-SPECT (3.48 +/- 1.21) (p = 0.01), Nonmalignant diffuse uptake of FDG in the breasts and the accumulation of MIBI in heart and liver occasionally obscured tumor uptake. Conclusion: These results indicate that MIBI-SPECT is comparable with FDG-PET in detecting breast cancer. Neither EDG-PET nor MIBI-SPECT is sufficiently sensitive to rule out axillary lymph node metastasis.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 34 条
[1]   Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET [J].
Adler, LP ;
Faulhaber, PF ;
Schnur, KC ;
AlKasi, NL ;
Shenk, RR .
RADIOLOGY, 1997, 203 (02) :323-327
[2]   EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET [J].
ADLER, LP ;
CROWE, JP ;
ALKAISI, NK ;
SUNSHINE, JL .
RADIOLOGY, 1993, 187 (03) :743-750
[3]   Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Bense, S ;
Ziegler, S ;
Laubenbacher, C ;
Romer, W ;
Pache, H ;
Herz, M ;
Allgayer, B ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1848-1857
[4]   Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Ziegler, S ;
Romer, W ;
Weber, W ;
Herz, M ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1204-1209
[5]  
Harris J.R., 1993, Principles and Practice of Oncology, V4, P1264
[6]   MEDICAL PROGRESS .1. BREAST-CANCER [J].
HARRIS, JR ;
LIPPMAN, ME ;
VERONESI, U ;
WILLETT, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (05) :319-328
[7]  
Higashi T, 1997, J NUCL MED, V38, P1337
[8]  
KAO CH, 1994, EUR J NUCL MED, V21, P432
[9]  
KHALKHALI I, 1994, J AM COLL SURGEONS, V178, P491
[10]  
KHALKHALI I, 1995, J NUCL MED, V36, P1784